Washington Dc, DCNCT05952037Now EnrollingIRB Ready

Waldenström's Macroglobulinemia Clinical Trial in Washington Dc, DC

Access cutting-edge waldenström's macroglobulinemia treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.

Sponsored by BeiGene

Quick Self-Assessment

See if you qualify for this Washington Dc location

Preparing your pre-screening questions...

Expert Care in Washington Dc

Access waldenström's macroglobulinemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related waldenström's macroglobulinemia treatment provided free

Apply for This Washington Dc Location

Check if you qualify for this waldenström's macroglobulinemia clinical trial in Washington Dc, DC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Washington Dc

    Convenient for DC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Washington Dc site if eligible
  4. 4Begin participation

About This Waldenström's Macroglobulinemia Study in Washington Dc

This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.

Sponsor: BeiGene

Who Can Participate

Inclusion Criteria

Clinical and definitive histologic diagnosis of WM.
Meeting ≥ 1 criterion for treatment according to consensus panel criteria from the 2nd International Workshop on Waldenström's Macroglobulinemia (IWWM).
For Cohorts 1-3, refractory or relapsed disease at study entry unless participants had intolerance to the most recent therapy. Refractory disease is defined as not attaining at least a major response, or progressing while on or within 6 months of completing therapy. Relapsed disease is defined as attaining at least a major response to therapy and meeting the criteria for disease progression beyond 6 months after completing therapy.
For Cohort 4, patients must not have received prior therapy for WM (except for plasmapheresis).
Adequate organ function.

Exclusion Criteria

Central nervous system (CNS) involvement by WM.
Transformation to aggressive lymphoma, such as diffuse large B-cell lymphoma.
History of other malignancies ≤ 2 years before study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Washington Dc?

Yes, this clinical trial (NCT05952037) has an active research site in Washington Dc, DC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Waldenström's Macroglobulinemia Treatment Options in Washington Dc, DC

If you're searching for waldenström's macroglobulinemia treatment options in Washington Dc, DC, this clinical trial (NCT05952037) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced waldenström's macroglobulinemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all waldenström's macroglobulinemia clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Washington Dc, DC

See all heart attack clinical trials recruiting in Washington Dc — not just this study.

Browse Heart Attack Trials in Washington Dc →

Browse More Trials by Condition

Heart Attack TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Washington Dc?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Washington Dc, DC